Evidence map›Paper›PMID 39225857›Full record

ArticleAnnals of surgical oncology2024

Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study.

Nobuhiro Nakazawa, Makoto Sohda, Nobuhiro Hosoi, Takayoshi Watanabe, Yuji Kumakura, Toshiki Yamashita, Naritaka Tanaka, Kana Saito, Akiharu Kimura, Kengo Kasuga and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Nobuhiro NakazawaDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan. nakazawa75@yahoo.co.jp.
Makoto SohdaDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Nobuhiro HosoiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Takayoshi WatanabeDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Yuji KumakuraDepartment of Surgery, Tonechuo Hospital, Numata, Gunma, Japan.
Toshiki YamashitaDepartment of Surgery, Subaru Health Insurance Society Ota Memorial Hospital, Ota, Gunma, Japan.
Naritaka TanakaDepartment of Surgery, Japanese Red Cross Haramachi Hospital, Agatsumagun, Gunma, Japan.
Kana SaitoDepartment of Surgery, Japan Community Healthcare Organization Gunma Central Hospital, Maebashi, Gunma, Japan.
Akiharu KimuraDepartment of Surgery, Kiryu Kosei General Hospital, Kiryu, Gunma, Japan.
Kengo KasugaDepartment of Gastroenterology, Isesaki Municipal Hospital, Isesaki, Gunma, Japan.
Kenji NakazatoDepartment of Surgery, Fujioka General Hospital, Fujioka, Gunma, Japan.
Daisuke YoshinariDepartment of Surgery, National Hospital Organization Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Hisashi ShimizuDepartment of Surgery, Japanese Red Cross Maebashi Hospital, Maebashi, Gunma, Japan.
Yasunari UbukataDepartment of Surgery, National Hospital Organization Takasaki General Medical Center, Takasaki, Gunma, Japan.
Hisashi HosakaDepartment of Gastroenterology, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan.
Akihiko SanoDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Makoto SakaiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Hiroomi OgawaDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Ken ShirabeDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.
Hiroshi SaekiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, 371-8511, Japan.

Funding

JSPS KAKENHI 23K15513
6 · The paper itself

Abstract

backgroundThere are few reports on conversion surgery (CS) after chemotherapy plus nivolumab as a first-line treatment in patients with unresectable advanced or recurrent gastric cancer (GC). This multicenter study was conducted to analyze real-world data on CS after chemotherapy plus nivolumab as a first-line treatment and to identify predictive biomarkers.

methodsThis multicenter study included 104 patients who received chemotherapy plus nivolumab as primary treatment for unresectable advanced recurrent GC from 12 institutes. We investigated and analyzed patient characteristics and blood test data in the presence or absence of CS, the relationship between the Gustave Roussy Immune Score (GRIm-s) and CS, and the characteristics of CS cases.

resultsCS was performed in 12 patients (11.5%). Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was significantly better in patients who underwent CS (p < 0.0001). There were no CS cases with high-risk GRIm-s (0%), however there were 22 non-CS cases (23.9%). No high-risk GRIm-s cases were converted to CS. Minimally invasive surgery was performed in 50.0% of the cases, with R0 resection in all cases and only one case of urinary retention (Grade II) as a postoperative complication, indicating a good postoperative short-term outcome. There were two cases of postoperative recurrence (16.7%), both of which were grade 1b.

conclusionsThe short-term postoperative results of CS after chemotherapy plus nivolumab as the first-line treatment for GC were acceptable in this study. There were no high-risk GRIm-s cases among those who underwent CS, suggesting that the GRIm-s may be a predictor of CS.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsGastrectomyNeoplasm Recurrence, LocalNivolumabStomach NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisBiomarkers, TumorNivolumabChemotherapyConversion surgeryGastric cancerGustave Roussy Immune ScoreNivolumab

Identifiers

PMID39225857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.